CVM stock forecast
Our latest prediction for CEL-SCI Corp.'s stock price was made on the Jan. 10, 2020 when the stock price was at 7.78$.
In the short term (2weeks), CVM's stock price should underperform the market by -5.56%. During that period the price should oscillate between -10.33% and +12.21%.
In the medium term (3months), CVM's stock price should underperform the market by -11.09%. During that period the price should oscillate between -45.25% and +27.91%.Get email alerts
About CEL-SCI Corp.
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.71$ per share.
The book value per share is 0.03$
Three months stock forecastJan. 10, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|